{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:15:28Z","timestamp":1759342528931},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,5,20]],"date-time":"2003-05-20T00:00:00Z","timestamp":1053388800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1007\/s00115-003-1513-6","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T19:01:59Z","timestamp":1478026919000},"page":"489-496","source":"Crossref","is-referenced-by-count":4,"title":["Morbus Fabry"],"prefix":"10.1007","volume":"74","author":[{"given":"A. J.","family":"Grau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schwaninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. H.","family":"Goebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,5,20]]},"reference":[{"key":"1513_CR1","doi-asserted-by":"crossref","unstructured":"Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, Panza JA, Schiffmann R (2001) Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32:1559\u20131562","DOI":"10.1161\/01.STR.32.7.1559"},{"key":"1513_CR2","unstructured":"Beck M, Whybra C, Kriegsmann J (2001) Morbus Fabry. Aktuelle therapeutische Perspektiven. Dtsch \u00c4rzteblt 98:394\u2013396"},{"key":"1513_CR3","doi-asserted-by":"crossref","unstructured":"Brady RO, Schiffmann R (2000) Clinical Features of and Recent Advances in Therapy for Fabry Disease. JAMA 284:2771\u20132775","DOI":"10.1001\/jama.284.21.2771"},{"key":"1513_CR4","doi-asserted-by":"crossref","unstructured":"Cable WJL, Kolodny EH, Adams RD (1982) Fabry disease: Impaired autonomic function. Neurology 32:498\u2013503","DOI":"10.1212\/WNL.32.5.498"},{"key":"1513_CR5","doi-asserted-by":"crossref","unstructured":"Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, Barton NW, Schiffmann R (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746\u20131749","DOI":"10.1212\/WNL.50.6.1746"},{"key":"1513_CR6","doi-asserted-by":"crossref","unstructured":"DeGraba T, Azhar S, Dignat-George F, Brown E, Bouti\u00e8re B, Altarescu G, McCarron R, Schiffmann R (2000) Profile of Endothelial and Leukocyte Activation in Fabry Patients. Ann Neurol 47:229\u2013233","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T"},{"key":"1513_CR7","unstructured":"Desnick RJ, Ioannou YA, Eng CM (2001) alpha-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, DV (eds) The metabolic and molecular bases of inherited disease. 8th. McGraw-Hill, New York, S\u00a0733\u2013774."},{"key":"1513_CR8","doi-asserted-by":"crossref","unstructured":"Eng CM, Banikazemi M, Gordon RE et al. (2001) A Phase 1\/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety Studies. Am J Hum Genet 68:711\u2013722","DOI":"10.1086\/318809"},{"key":"1513_CR9","doi-asserted-by":"crossref","unstructured":"Eng CM, Guffon N, Wilcox WR et al. (2001) Safety and Efficacy of Recombinant Human Alpha-Galactosidase A Replacement Therapy in Fabry`s Disease. N Engl J Med 345:9\u201316","DOI":"10.1056\/NEJM200107053450102"},{"key":"1513_CR10","doi-asserted-by":"crossref","unstructured":"Germain D (2002) Fabry disease: recent advances in enzyme replacment therapy. Expert Opin Investig Drugs 11:1467\u20131476","DOI":"10.1517\/13543784.11.10.1467"},{"key":"1513_CR11","doi-asserted-by":"crossref","unstructured":"Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, Pashos CL (2002) Quality of life of patients with Fabry disease. Qual Life Res 11:317\u2013327","DOI":"10.1023\/A:1015511908710"},{"key":"1513_CR12","doi-asserted-by":"crossref","unstructured":"Grewal, R (1994) Stroke in Fabry`s disease. J Neurol 241:153\u2013156","DOI":"10.1007\/BF00868342"},{"key":"1513_CR13","doi-asserted-by":"crossref","unstructured":"Hilz MJ, Stemper B, Kolodny EH (2000) Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 84:361\u2013365","DOI":"10.1016\/S0304-3959(99)00236-5"},{"key":"1513_CR14","doi-asserted-by":"crossref","unstructured":"Luciano CA, Russell JW, Banerjee TK et al. (2002) Physiological characterization of neuropathy in Fabry`s disease. Muscle Nerve 26:622\u20139","DOI":"10.1002\/mus.10236"},{"key":"1513_CR15","doi-asserted-by":"crossref","unstructured":"MacDermot J, MacDermot KD (2001) Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. European Journal of Pharmacology 429:121\u2013125","DOI":"10.1016\/S0014-2999(01)01312-7"},{"key":"1513_CR16","doi-asserted-by":"crossref","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate females carrier . J Med Genet 38:769\u2013807","DOI":"10.1136\/jmg.38.11.769"},{"key":"1513_CR17","doi-asserted-by":"crossref","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750\u2013760","DOI":"10.1136\/jmg.38.11.750"},{"key":"1513_CR18","doi-asserted-by":"crossref","unstructured":"Mehta A (2002) New developments in the management of Anderson-Fabry disease. Q J Med 95:647\u2013653","DOI":"10.1093\/qjmed\/95.10.647"},{"key":"1513_CR19","doi-asserted-by":"crossref","unstructured":"Mitsias P, Levine SR (1996) Cerebrovascular Complications of Fabry`s Disease. Ann Neurol 40:8\u201317","DOI":"10.1002\/ana.410400105"},{"key":"1513_CR20","doi-asserted-by":"crossref","unstructured":"Mohanraj R, Leach JP, Broome JC, Smith DF (2002) Neurological presentation of Fabry`s disease in a 52\u00a0year old man. J Neurol Neurosurg Psychiatry 73:340\u20132","DOI":"10.1136\/jnnp.73.3.340"},{"key":"1513_CR21","doi-asserted-by":"crossref","unstructured":"Moore DF, Altarescu G, Ling GS et al. (2002) Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33:525\u2013531","DOI":"10.1161\/hs0202.102601"},{"key":"1513_CR22","doi-asserted-by":"crossref","unstructured":"Moore DF, Scott LT, Gladwin MT et al. (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506\u20131512","DOI":"10.1161\/hc3801.096352"},{"key":"1513_CR23","unstructured":"Morgan SH, Rudge P, Smith SJ et al. (1990) The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)\u2014investigation of symptomatic and presymptomatic patients. Q J Med 75:491\u2013507"},{"key":"1513_CR24","unstructured":"Perrot X, Nighoghossian N, Drex L, Hermier M, Guffon N, Boulliat J, Trouillas P (2002) Vertebro-basilar ischemic strokes and aseptic meningitis, late complications of Fabry`s disease. Rev Neurol (Paris) 158:596\u20138"},{"key":"1513_CR25","doi-asserted-by":"crossref","unstructured":"Schiffmann R (2001) Natural history of Fabry disease in males: preliminary observations. J. Inherit. Metab. Dis. 24:15\u201317","DOI":"10.1023\/A:1012499119196"},{"key":"1513_CR26","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20139","DOI":"10.1001\/jama.285.21.2743"},{"key":"1513_CR27","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Murray GJ, Treco D et al. (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Pro Natl Acad Sci USA 97:365\u2013370","DOI":"10.1073\/pnas.97.1.365"},{"key":"1513_CR28","doi-asserted-by":"crossref","unstructured":"Scott LJC, Griffin JW, Luciano C et al. (1999) Quantitative analysis of epidermal innervation in Fabry disease. Neurology 52:1249\u20131254","DOI":"10.1212\/WNL.52.6.1249"},{"key":"1513_CR29","doi-asserted-by":"crossref","unstructured":"Tedeschi G, Bonavita S, Banerjee TK, Virta A, Schiffmann R (1999) Diffuse central neuronal involvement in Fabry disease A proton MRS imaging study. Neurology 52:1663\u20131667","DOI":"10.1212\/WNL.52.8.1663"},{"key":"1513_CR30","doi-asserted-by":"crossref","unstructured":"Whybra C, Kampmann C, Willers I et al. (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24:715\u2013724","DOI":"10.1023\/A:1012993305223"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-003-1513-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-003-1513-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-003-1513-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-003-1513-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:00:39Z","timestamp":1558587639000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-003-1513-6"}},"subtitle":["Eine lysosomale Stoffwechselerkrankung mit neuen therapeutischen M\u00f6glichkeiten"],"short-title":[],"issued":{"date-parts":[[2003,5,20]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1007\/s00115-003-1513-6","relation":{},"ISSN":["0028-2804"],"issn-type":[{"value":"0028-2804","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5,20]]}}}